Aflibercept Outperforms Ranibizumab in Cases of Serous Pigment Epithelium Detachment from Neovascular AMD


An optical coherence tomography study found that, after three monthly treatments,aAflibercept was 7 times more effective than ranibizumab in resolving serous pigment epithelium detachment, though neither treatment improved visual acuity in these patients to a statistically significant degree.

aflibercept, age-related macular degeneration, anti-vascular endothelial growth factor agents, best corrected visual acuity, central foveal thickness, external limiting membrane, Aflibercept, fibrovascular, hyper-reflective dots, inner segment, intraretinal fluid, intravitreal injection, length, Ranibizumab, ophthalmology, optical coherence tomography, outer segment, pigment epithelium detachment, ranibizumab, serous pigment epithelium detachment, subretinal fluid, treatment-naïve, visual acuity

A team of researchers at the Department of Ophthalmology at A University Hospital in Busan, South Korea, studied 63 patients with neovascular age-related macular degeneration (nAMD) to assess the differences in optical coherence tomography (OCT) findings between patients treated with aflibercept and those treated with ranibizumab.

These treatment-naïve patients received an intravitreal injection of aflibercept or ranibizumab once monthly for 3 months. For each treatment group, the team compared findings during baseline OCT with OCT findings after treatment. The team published the results of their study in a special issue of Acta Ophthalmologica containing abstracts of the 2016 European Association for Vision and Eye Research Conference.

  • OCT findings of interest included the following:
  • Serous pigment epithelium detachment
  • Fibrovascular pigment epithelium detachment
  • Subretinal fluid
  • Intraretinal fluid
  • Dense zone of the outer retina
  • Classic neovascularization
  • Hyper-reflective dots.

The team also compared baseline and post-treatment values between the two treatment groups with respect to the following:

  • Best corrected visual acuity (BCVA)
  • Inner segment/outer segment (IS/OS) length
  • External limiting membrane (ELM) length
  • Central foveal thickness

The team noted no statistically significant differences between the two groups before treatment. However, after treatment, a significant difference in the rate of disappearance of serous pigment epithelium detachment was found between the aflibercept group and the ranibizumab group (36% vs. 5%, respectively, P = 0.02).

The team found no significant differences between treatment groups in changes from before treatment to after treatment in other OCT findings or in BCVA.

These findings led the team to conclude that aflibercept might be more effective than ranibizumab specifically for the treatment of nAMD patients with serous pigment epithelium detachment.

In addition, because they found no statistically significant improvement in visual acuity after either treatment in patients with serous pigment detachment in this study, they recommended further study of the relation between visual acuity and improvement in serous pigment detachment.

Related Coverage:

End-Stage Renal Disease Elevates Risk of Macular Degeneration

Central Foveal Thickness Cut-off Value Identified for Corticosteroid Treatment in Intermediate Uveitis

In Neovascular Age-Related Macular Degeneration, Lucentis and Eylea Yield Similar Injection Burden

Related Videos
Etienne Sibille, PhD: Innovations in Cognitive Pathology
Roger Goldberg, MD: Impact of Dual Inhibition on Hard Exudates in DME | Image Credit: Bay Area Retina Associates
Deepayan Kar, PhD, MS: A Virtual Reality Approach to Contrast Sensitivity in AMD | Image Credit: LinkedIn
Dolly Chang, MD, PhD | Image Credit: LinkedIn
Daniel Su, MD: | Image Credit: Retina Vitreous-Associates Medical Group
Daniela Ferrara, MD, PhD: Machine Learning Predicts Functional Outcomes in DME | Image Credit: Ophthalmology Innovation Summit
Ashkan Abbey, MD: 3-Year Efficacy of Pegcetacoplan for Geographic Atrophy | Image Credit: Texas Retina AssociatesImage Credit:
© 2024 MJH Life Sciences

All rights reserved.